據報陽光城對已到期產品安排兩方案 涉展期及以房屋資產兌付
陽光城(000671.SZ)兄弟公司陽光金服旗下華冕財富理財產品兌付將採取展期或以房屋兌付的方式解決。
據《21世紀經濟報道》獲悉,經多次研究,陽光城對未來幾個月已到期產品做出安排包括兩方案,方案一爲,展期6+6個月。展期期間,投資的最終兌付義務方將爲展期產品提供足額增信。方案二爲,實物資產兌付。合同約定期限到期的投資產品,以及合同約定期限未到期但投資人要求提前以實物形式兌付的投資產品,投資人可以選擇該方案。由各地區公司提供已獲取預售證、可供兌付的全資項目實物資產供投資人選擇,包括住宅、公寓、寫字樓、商鋪、車位等。
至於未到期產品安排爲,投資人所有未到期產品均按合同約定的利率正常計息支付。(ta/s) ~
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.